Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Exon-based phylogenomics strengthens the phylogeny of Neotropical cichlids and identifies remaining conflicting clades (Cichliformes: Cichlidae: Cichlinae).

Ilves KL, Torti D, López-Fernández H.

Mol Phylogenet Evol. 2018 Jan;118:232-243. doi: 10.1016/j.ympev.2017.10.008. Epub 2017 Oct 12.

PMID:
29031585
2.

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, Volante M, Morena D, Lingua MF, Brancaccio M, Guerrasio A, Pandolfi PP, Saglio G, Taulli R, Morotti A.

Oncotarget. 2017 May 30;8(22):35508-35522. doi: 10.18632/oncotarget.16348.

3.

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.

Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review.

4.

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

Morotti A, Torti D, Carra G, Panuzzo C, Crivellaro S, Taulli R, Fava C, Guerrasio A, Saglio G.

Curr Drug Targets. 2017;18(4):389-395. doi: 10.2174/1389450117666160608120527. Review.

PMID:
27291926
5.

Diffusion-weighted quantitative MRI to diagnose benign conditions from malignancies of the anterior mediastinum: Improvement of diagnostic accuracy by comparing perfusion-free to perfusion-sensitive measurements of the apparent diffusion coefficient.

Priola AM, Priola SM, Gned D, Piacibello E, Sardo D, Parvis G, Torti D, Ardissone F, Veltri A.

J Magn Reson Imaging. 2016 Sep;44(3):758-69. doi: 10.1002/jmri.25203. Epub 2016 Feb 19.

PMID:
26892919
6.

The Role of PTEN in Myeloid Malignancies.

Morotti A, Panuzzo C, Crivellaro S, Carrà G, Torti D, Guerrasio A, Saglio G.

Hematol Rep. 2015 Dec 9;7(4):5844. doi: 10.4081/hr.2015.6027. eCollection 2015 Nov 23. Review.

7.

New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia.

Panuzzo C, Volpe G, Cibrario Rocchietti E, Casnici C, Crotta K, Crivellaro S, Carrà G, Lorenzatti R, Peracino B, Torti D, Morotti A, Camacho-Leal MP, Defilippi P, Marelli O, Saglio G.

Oncoscience. 2015 Nov 11;2(10):880-91. eCollection 2015.

8.

Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.

Crivellaro S, Panuzzo C, Carrà G, Volpengo A, Crasto F, Gottardi E, Familiari U, Papotti M, Torti D, Piazza R, Redaelli S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2015 Sep 22;6(28):25217-25. doi: 10.18632/oncotarget.4611.

9.

Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes.

Ammar R, Paton TA, Torti D, Shlien A, Bader GD.

Version 2. F1000Res. 2015 Jan 21 [revised 2015 Jan 1];4:17. doi: 10.12688/f1000research.6037.2. eCollection 2015.

10.

Usefulness of diffusion-weighted magnetic resonance imaging for assessing early treatment response in lymphoma patients.

Priola AM, Gned D, Parvis G, Torti D, Priola SM.

Acta Radiol. 2015 Feb;56(2):NP10-1. doi: 10.1177/0284185114554254. Epub 2014 Oct 20. No abstract available.

PMID:
25332443
11.

A genome scale overexpression screen to reveal drug activity in human cells.

Arnoldo A, Kittanakom S, Heisler LE, Mak AB, Shukalyuk AI, Torti D, Moffat J, Giaever G, Nislow C.

Genome Med. 2014 Apr 29;6(4):32. doi: 10.1186/gm549. eCollection 2014.

12.

Miniature short hairpin RNA screens to characterize antiproliferative drugs.

Kittanakom S, Arnoldo A, Brown KR, Wallace I, Kunavisarut T, Torti D, Heisler LE, Surendra A, Moffat J, Giaever G, Nislow C.

G3 (Bethesda). 2013 Aug 7;3(8):1375-87. doi: 10.1534/g3.113.006437.

13.

Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations.

Hill JA, Ammar R, Torti D, Nislow C, Cowen LE.

PLoS Genet. 2013 Apr;9(4):e1003390. doi: 10.1371/journal.pgen.1003390. Epub 2013 Apr 4.

14.

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.

Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G.

Leuk Res. 2013 May;37(5):520-30. doi: 10.1016/j.leukres.2013.01.014. Epub 2013 Feb 12.

PMID:
23415111
15.

Chromatin is an ancient innovation conserved between Archaea and Eukarya.

Ammar R, Torti D, Tsui K, Gebbia M, Durbic T, Bader GD, Giaever G, Nislow C.

Elife. 2012 Dec 13;1:e00078. doi: 10.7554/eLife.00078.

16.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.

Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.

17.

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L.

Oncogene. 2013 Mar 14;32(11):1428-40. doi: 10.1038/onc.2012.154. Epub 2012 May 7.

18.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5.

19.

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils.

Torti D, Trusolino L.

EMBO Mol Med. 2011 Nov;3(11):623-36. doi: 10.1002/emmm.201100176. Epub 2011 Sep 23. Review.

20.

Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.

Torti DC, Christensen BC, Storm CA, Fortuny J, Perry AE, Zens MS, Stukel T, Spencer SK, Nelson HH, Karagas MR.

J Am Acad Dermatol. 2011 Aug;65(2):304-312. doi: 10.1016/j.jaad.2010.05.042. Epub 2011 May 6.

21.

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.

Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM, Trusolino L, Bertotti A.

Int J Cancer. 2012 Mar 15;130(6):1357-66. doi: 10.1002/ijc.26137. Epub 2011 May 30.

22.

Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2011 May 15;17(10):3146-56. doi: 10.1158/1078-0432.CCR-10-3377. Epub 2011 Mar 29.

23.

Spitz nevi arising in speckled lentiginous nevus: clinical, histologic, and molecular evaluation of two cases.

Torti DC, Brennick JB, Storm CA, Dinulos JG.

Pediatr Dermatol. 2011 Sep-Oct;28(5):561-7. doi: 10.1111/j.1525-1470.2011.01239.x. Epub 2011 Mar 3.

PMID:
21371116
24.

Inhibition of Src impairs the growth of met-addicted gastric tumors.

Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.

Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13.

25.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009;2(102):er11.

PMID:
20039471
26.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Erratum in: Sci Signal. 2009 Dec 22;2(102):er11. Corrected and republished in: Sci Signal. 2009;2(102):er11.

27.

Managing hot flashes in men being treated for prostate cancer.

Baum NH, Torti DC.

Geriatrics. 2007 Nov;62(11):18-21. Review.

PMID:
17999566
28.

Interleukin-12, interleukin-23, and psoriasis: current prospects.

Torti DC, Feldman SR.

J Am Acad Dermatol. 2007 Dec;57(6):1059-68. Epub 2007 Aug 15. Review.

PMID:
17706835
29.

Oral lichen planus: a case series with emphasis on therapy.

Torti DC, Jorizzo JL, McCarty MA.

Arch Dermatol. 2007 Apr;143(4):511-5.

PMID:
17438185
30.

CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome.

Heisler LE, Torti D, Boutros PC, Watson J, Chan C, Winegarden N, Takahashi M, Yau P, Huang TH, Farnham PJ, Jurisica I, Woodgett JR, Bremner R, Penn LZ, Der SD.

Nucleic Acids Res. 2005 May 23;33(9):2952-61. Print 2005.

31.

Exercise and prostate cancer.

Torti DC, Matheson GO.

Sports Med. 2004;34(6):363-9. Review.

PMID:
15157121
32.

[A case of cyanide poisoning].

Melloni C, Corticelli AS, Di Nino GF, Mazzetti P, Torti D.

Minerva Anestesiol. 1983 Sep;49(9):527-30. Italian. No abstract available.

PMID:
6419176

Supplemental Content

Support Center